VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIA
患有精神分裂症的吸烟者吸食的尼古丁含量非常低
基本信息
- 批准号:8153488
- 负责人:
- 金额:$ 27.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-15 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AbstinenceAcuteAftercareBehavioralBenefits and RisksBiological MarkersCigaretteComplementDoseGeneral PopulationHealth PolicyHumanInstructionKnowledgeLaboratory StudyLongevityMeasuresMethodsMinorityMoodsMorbidity - disease rateNeurobehavioral ManifestationsNicotinePatternPerformancePhasePopulationPrevalencePublic HealthRandomizedSchizophreniaSelf MedicationSmokeSmokerSmokingSymptomsTimeTobaccoTobacco useUnited StatesWithdrawalWithdrawal SymptomWithholding Treatmentcigarette smokingcognitive functioncravingcue reactivityinnovationmortalitynegative moodresponsesatisfactionsevere mental illnesssmoking cessationtreatment duration
项目摘要
Nearly half of the tobacco consumed in the United States is smoked by people with psychiatric illness. In
particular, smokers with schizophrenia (SWS) infrequently attempt and attain sustained smoking abstinence
and have a 25-year shorter lifespan due to smoking-related illness. SWS are in dire need of effective
smoking treatment and are not benefiting from treatments that are currently available. Reducing the nicotine
content of cigarettes to non-addicting levels is an innovative strategy that has the potential to significantly
reduce tobacco-related morbidity and mortality in this population. In evaluating the potential impact of this
strategy, one critical knowledge gap that was identified is whether this strategy would be effective in smokers
with serious mental illness, who are more nicotine-dependent than other smokers and who may smoke for
self-medication purposes. We are currently studying the acute effects of VLNC cigarettes in SWS, with
promising results showing that use of these cigarettes reverses abstinence-induced cigarette craving,
withdrawal-related negative mood and usual-brand smoking. Furthermore, SWS rate the subjective effects
VLNC cigarettes highly, indicating that such an approach may be acceptable to SWS. However, the effects
of prolonged use of VLNC cigarettes on smoking tiehavior, psychiatric symptoms and cognitive functioning in
SWS are unknown. This study would be the first to examine whether a regulatory approach of reducing the
nicotine content of cigarettes to non-addicting levels is a viable method of reducing smoking in this
population. Smokers will be randomized to one of two experimental conditions: 1) very low nicotine content
(VLNC) cigarettes with a 0.06 mg nicotine yield (actual dose to be determined by Project 1; n = 40), or 2)
normal nicotine content cigarettes (n = 40). Over the 2-week baseline and 6-week treatment phases,
subjects will be assessed for patterns of tobacco use, biomarkers of exposure, subjective responses (e.g.,
satisfaction, craving, withdrawal symptoms), psychiatric symptoms, cognitive performance, smoking cue
reactivity and smoking topography. At the end of the 6-week treatment period, subjective and behavioral
responses to smoking abstinence will be assessed. The results from this study will describe the possible
risks and benefits to smokers with schizophrenia of dramatically reducing the nicotine content of cigarettes.
This project will complement and use similar measures as Projects 1 and 2.
RELEVANCE (See instructions);
There is an unusually high rate of cigarette smoking and correspondingly high rates of smoking-related
morbidity and mortality in smokers with schizophrenia. This project will investigate the effects of 6-week use
of very low nicotine content cigarettes on smoking, mood, psychiatric symptoms, cognitive functioning and
other measures in smokers with schizophrenia. This information will help to determine whether a public
health policy of limiting the nicotine content of cigarettes to very low levels would be effective and safe for
these smokers
在美国,近一半的烟草消费是由患有精神疾病的人抽的。在
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JENNIFER W. TIDEY其他文献
JENNIFER W. TIDEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JENNIFER W. TIDEY', 18)}}的其他基金
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
弱势群体中的低尼古丁含量香烟:情感障碍
- 批准号:
10247028 - 财政年份:2013
- 资助金额:
$ 27.92万 - 项目类别:
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
弱势群体中的低尼古丁含量香烟:情感障碍
- 批准号:
10477408 - 财政年份:2013
- 资助金额:
$ 27.92万 - 项目类别:
Acute Effects of Exercise in Smokers with Schizophrenia
运动对患有精神分裂症的吸烟者的急性影响
- 批准号:
8240630 - 财政年份:2012
- 资助金额:
$ 27.92万 - 项目类别:
Acute Effects of Exercise in Smokers with Schizophrenia
运动对患有精神分裂症的吸烟者的急性影响
- 批准号:
8424266 - 财政年份:2012
- 资助金额:
$ 27.92万 - 项目类别:
VERY LOW NICOTINE CIGARETTES IN SMOKERS WITH SCHIZOPHRENIA
患有精神分裂症的吸烟者吸食的尼古丁含量非常低
- 批准号:
8379278 - 财政年份:2011
- 资助金额:
$ 27.92万 - 项目类别:
Smoking abstinence and lapse effects in smokers with schizophrenia and controls
精神分裂症吸烟者和对照组吸烟者的戒烟和戒烟效果
- 批准号:
7693102 - 财政年份:2009
- 资助金额:
$ 27.92万 - 项目类别:
Incentives Plus Bupropion for Smoking in Schizophrenics
精神分裂症患者吸烟的激励加安非他酮
- 批准号:
6806072 - 财政年份:2003
- 资助金额:
$ 27.92万 - 项目类别:
Incentives Plus Bupropion for Smoking in Schizophrenics
精神分裂症患者吸烟的激励加安非他酮
- 批准号:
6920591 - 财政年份:2003
- 资助金额:
$ 27.92万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 27.92万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 27.92万 - 项目类别:
Operating Grants














{{item.name}}会员




